DETMED Mid-Term Meeting in Lisbon

On February 20, 2025, Universidade Lusófona - Centro Universitário de Lisboa hosted the Mid-Term Meeting of the DETMED project, an initiative funded by the European Commission's European Research Executive Agency (REA) and coordinated by the institution itself.

The project aims to develop an innovative prototype of a compact, high-precision gamma probe to optimize the surgical removal of tumours, increasing the effectiveness of cancer diagnosis and treatment. Through advanced research in optoelectronics and the application of cutting-edge technologies, DETMED is relying on international collaboration to boost the new generation of high-sensitivity gamma detectors, bringing together experts from Portugal, Poland, the Czech Republic, Slovenia, Ukraine, Germany, Hungary and Azerbaijan.

During the meeting, the consortium teams presented the most recent advances in the project and outlined the next steps to be taken in the different Work Packages (WP), with emphasis on the preparation and testing of innovative SiPM samples, the investigation of scintillating material parameters, the development of the electronic circuit and the gamma probe reading system, as well as the overall management of the project. In addition to the technical progress, the mobile researchers shared their experiences and contributions to the advancement of research.

The event was attended in person and online by all the consortium members, including Universidade Lusófona/COFAC (Portugal), CascataChuva LDA (Portugal), Institute of General and Inorganic Chemistry of the National Academy of Sciences of Ukraine VI Vernadsky (Ukraine), Nanomaterials Research & Development (Poland), Elmek Mozgasban Alapítvány (Hungary), Technical University of Dortmund (Germany), Jožef Stefan Institute (Slovenia), University of West Bohemia (Czech Republic), Institute of Radiation Problems of the National Academy of Sciences of Azerbaijan and SETM LLC (Azerbaijan). The European Union was represented by a member of the REA, reinforcing its commitment to innovation and research in the fight against cancer. With the advances presented, the project is now moving on to the next stages of development, aiming to revolutionize the precision of medical procedures and contribute to significant improvements in the care of cancer patients.